Lipids and vascular disease: what we do and do not know (Q33746602)

29 July 2017

1 reference

title

Lipids and vascular disease: what we do and do not know (English)

1 reference

29 July 2017

1 reference

1

Sniderman AD

1 reference

29 July 2017

2

Cianflone K

1 reference

29 July 2017

1 August 1999

1 reference

29 July 2017

1 reference

29 July 2017

286

1 reference

29 July 2017

1-2

1 reference

29 July 2017

7-22

1 reference

Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Relationship between plasma lipid concentrations and coronary artery disease in 496 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Association of risk factor variables and coronary artery disease documented with angiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Apolipoprotein B: structure, biosynthesis and role in the lipoprotein assembly process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Québec Cardiovascular Study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Myocardial infarction in the familial forms of hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Clinical significance of measurements of serum apolipoprotein A-I, A-II and B in hypertriglyceridemic male patients with and without coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Reductase inhibitor monotherapy and stroke prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2899%2900090-X

10.1016/S0009-8981(99)00090-X

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10511281